Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 125 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: AZD6140 Clear all
Completed No phase listed Observational

Platelet Sub-study of the TWILIGHT Trial

NCT04001374
View directory record Official record
Conditions
Coronary Artery Disease, Myocardial Infarction
Interventions
Ticagrelor, ASA
Drug
Lead sponsor
Juan Badimon
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 26, 2026, 2:17 AM EDT
Recruiting Phase 4 Interventional

Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors

NCT06691191
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor 90 mg, Prasugrel 10 mg
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 26, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on Platelets

NCT01744288
View directory record Official record
Conditions
Inhibition on Platelet Aggregation
Interventions
Ticagrelor, Clopidogrel, ASA
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
258 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Oct 26, 2026, 2:17 AM EDT
Not listed Phase 4 Interventional

Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI

NCT02012140
View directory record Official record
Conditions
Cardiovascular Disease, Stable Angina, Myocardial Infarction, Coronary Artery Disease
Interventions
ticagrelor
Drug
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Oct 26, 2026, 2:17 AM EDT
Terminated Phase 4 Interventional Results available

Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.

NCT02052635
View directory record Official record
Conditions
Non-ST Elevation Acute Coronary Syndrome
Interventions
ticagrelor, clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Jacksonville, Florida • Lake Mary, Florida • Macon, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 27, 2016 · Synced Oct 26, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers

NCT00733265
View directory record Official record
Conditions
Renal Impairment
Interventions
AZD6140
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
4
States / cities
Phoenix, Arizona • Anaheim, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2010 · Synced Oct 26, 2026, 2:17 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Switch to Ticagrelor in Critical Limb Ischemia Anti-platelet Study

NCT02091921
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Ticagrelor
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 26, 2026, 2:17 AM EDT
Completed Phase 4 Interventional Results available

A Pharmacodynamic Study With Ticagrelor in African American Patients

NCT01523392
View directory record Official record
Conditions
Stable Coronary Artery Disease
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Newark, Delaware • Wilmington, Delaware • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Oct 26, 2026, 2:17 AM EDT
Completed No phase listed Observational

Replication of the ISAR-REACT 5 Antiplatelet Trial in Healthcare Claims Data

NCT05086081
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Ticagrelor 90mg, Prasugrel 10mg
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
28,389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 26, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

NCT01732822
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 130 Years
Enrollment
13,885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
290
States / cities
Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 239 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Oct 26, 2026, 2:17 AM EDT
Completed Phase 4 Interventional Results available

Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention

NCT02270242
View directory record Official record
Conditions
Cardiovascular Disease, Interventional Cardiology
Interventions
Aspirin, Placebo, ticagrelor
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
9,006 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Oct 26, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 in Healthy Volunteers

NCT03492385
View directory record Official record
Conditions
Healthy
Interventions
PB2452 Infusion, Placebo - Sodium Chloride, Ticagrelor Oral Tablet - Pre-Treatment, Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment
Drug
Lead sponsor
SFJ Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 26, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Results available

A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease

NCT02214121
View directory record Official record
Conditions
Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease
Interventions
Ticagrelor Dose 1a + Dose 2a, Ticagrelor Dose 1b + Dose 2b
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
2 Years to 17 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Orange, California • Chicago, Illinois • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2018 · Synced Oct 26, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin

NCT00528411
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor Tablets, Clopidogrel (over encapsulated) capsule, Aspirin Tablets
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Baton Rouge, Louisiana • Baltimore, Maryland • Towson, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Oct 26, 2026, 2:17 AM EDT
Withdrawn Phase 2 Interventional

Ticagrelor vs. Prasugrel Effects on Infarct Size

NCT02507323
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
ticagrelor, prasugrel, Placebo
Drug
Lead sponsor
Yochai Birnbaum
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Oct 26, 2026, 2:17 AM EDT
Terminated Phase 2 Interventional Results available

Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR

NCT02227368
View directory record Official record
Conditions
Peripheral Artery Disease (PAD)
Interventions
Ticagrelor, Comparator
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 130 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Daytona Beach, Florida • Jacksonville, Florida • Ocala, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 26, 2026, 2:17 AM EDT
Completed Phase 4 Interventional Results available

Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease

NCT02287909
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Clopidogrel, Ticagrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 26, 2026, 2:17 AM EDT
Not listed Phase 2Phase 3 Interventional

Half-dose Ticagrelor Overcomes High-dose Clopidogrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity

NCT03062462
View directory record Official record
Conditions
Coronary Artery Disease, Clopidogrel, Poor Metabolism of
Interventions
Clopidogrel, ticagrelor
Drug
Lead sponsor
First Affiliated Hospital of Harbin Medical University
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Havertown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 26, 2026, 2:17 AM EDT
Completed Phase 4 Interventional Results available

Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease

NCT02539160
View directory record Official record
Conditions
Coronary Artery Disease, Diabetes Mellitus
Interventions
ticagrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 26, 2026, 2:17 AM EDT
Completed No phase listed Observational

Patient Characteristics, Persistence to Treatment and Outcome Events in Patients Treated With Ticagrelor 60 mg After Myocardial Infarction in Real-world Clinical Practice

NCT04568083
View directory record Official record
Conditions
Myocardial Infarction (MI)
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
Up to 130 Years
Enrollment
7,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Bethesda, Maryland • Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Oct 26, 2026, 2:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis

NCT02335099
View directory record Official record
Conditions
End Stage Renal Disease, Vascular Access Patency
Interventions
ticagrelor, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Oct 26, 2026, 2:17 AM EDT
Completed Phase 4 Interventional Results available

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study

NCT03489863
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Ticagrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 26, 2026, 2:17 AM EDT
Active, not recruiting Phase 3 Interventional

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

NCT05047172
View directory record Official record
Conditions
Intracranial Arteriosclerosis, Stroke
Interventions
Ticagrelor + Aspirin, Rivaroxaban + Aspirin, Clopidogrel + Aspirin, Risk Factor Management
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
30 Years and older
Enrollment
1,683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
114
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 26, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

NCT00391872
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
18,624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
139
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 136 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Oct 26, 2026, 2:17 AM EDT